Safety Endpoints

(208) Misclassification of Metformin and Insulin Exposure Among Individuals with Type 2 Diabetes Using Integrated Electronic Health Record and Pharmacy Claims Data

(209) Optimization-based Stable Balancing Weights vs. Propensity Score Weighting for Samples with High Covariate Imbalance

(210) Validation of alopecia coding in US claims data among women of childbearing age

(211) Machine Learning Based Prediction of Serious Adverse Events in Metastatic Breast Cancer Patients Receiving Zoledronic Acid

(212) Personalized Prescribing Portraits and Evidence Summaries on First-line Antihypertensive Prescribing: A Factorial Randomized Trial of Audit-and-Feedback

(213) Variable Selection for Transporting Estimates to Specific Target Populations

(214) Validation of Indication for Use (INDO) in the Danish National Prescription Registry

(215) Anticholinergic medication used and the risk of delirium in people with dementia- A self-controlled case series study

(216) Comparative safety of baricitinib versus TNFi in Rheumatoid Arthritis management in the French population: a propensity score-matched cohort study

(217) Risk Assessment of Hypocalcaemia in Patients with Renal Impairment Prescribed Bisphosphonate Preparations Using the MID-NET® in Japan

(218) Validity of an ICD-10 Algorithm for Nonfatal Myocardial Infarction Among US Medicare Older Adults

(219) Cardiovascular Risk Among Benign Prostatic Hyperplasia Patients Receiving Alpha Blockers and 5-Alpha Reductase Inhibitors

(220) Compliance of oral isotretinoin use with prescription and delivery guidelines between 2014 and 2021 in France

(222) Defining Provider Prescribing Preference as an Instrumental Variable: A Case Study of NOACs in Stroke Prevention

(223) A simulation-based approach to assess the potential impact of unmeasured confounding on study validity at the design stage of non-interventional studies

(224) Validity of ICD-10 Algorithms for Ischemic and Hemorrhagic Stroke in US Medicare Older Adults

(225) A statistical test for differential sensitivity of study outcome

(226) Risk of Type 2 Diabetes Mellitus and Hyperlipidemia in Patients With Chronic Myeloid Leukemia Initiating Tyrosine Kinase Inhibitors: A Nationwide Cohort Study

(227) Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis

(228) Validity of a Claims-Based Algorithm to Identify Lactic Acidosis in US Medicare

(229) Validity of Claims-Based Algorithm to Identify Venous Thromboembolism in Japan

(230) Methodological approach for estimating the prevalence of rare cancers in DARWIN EU®

(231) Evidence Supporting Product Withdrawals for Safety Reasons in Europe: Shift of the Trend Over Time

(232) Understanding Data Source Characteristics Triggering Heterogeneity When Pooling RWD Sources in Pharmacoepidemiological Studies

(233) Real-World Incidence of Selected Clinical Events in Patients Diagnosed with Myelofibrosis

(234) An iterative phenotype development and evaluation process with medical specialist input: the experience defining progressive multifocal leukoencephalopathy

(235) Statin use and sensorineural hearing loss in patients with type 2 diabetes: Evidence from a population-based case-control study

(236) Risk factors associated with the incidence of Tyrosine kinase inhibitors-induced cardiac toxicity in cancer patients: a population-based case-control study

(237) Polypharmacy and Hyperpolypharmacy among Patients with Chronic Kidney Disease: Prevalence, Geographical Difference, and Associated Factors

(238) Real-world Effectiveness and Safety of Multiple Myeloma Treatments Based on Thalidomide and Bortezomib: a Retrospective Cohort Study from 2009 to 2020 in a Brazilian Metropolis

(239) Effect of Statin Use for the Primary Prevention of Cardiovascular Disease Among Older Adults: An Observational Analysis Emulating a Target Trial

(240) Bridging clinical trial life expectancy (LE) inclusion criterion in the real-world (RW) setting: targeted literature review results for modeling feasibility in relapsed and refractory multiple myeloma (RRMM) patients

(241) Assessment of Chemotherapy-Induced Nausea and Vomiting strategies in a resource-constraint setting

(242) Using Real World Data to Inform Clinical Trial Design

(243) Prescription trends of PCSK9 inhibitors in Hong Kong

(244) A comparative safety study of generic alendronate tablet using claims database

(245) Percutaneous Transluminal Septal Myocardial Ablation and Common Procedural Complications before and after the approval of Ablysinol

(246) Development and Validation of Algorithms to Identify Endometrial Carcinoma Using ICD-9 and ICD-10 Codes in a US Healthcare Claims Database

(247) Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D)

(248) Application of Machine Learning methods for Prediction of Tyrosine kinase inhibitor-induced hepatotoxicity in Cancer Patients

(249) Validation of Diagnoses of Hepatic Disorders in Users of Systemic Antifungal Medication in Sweden

(250) The risk of psychiatric hospitalization with medical cannabis: self-controlled case series study

(251) Assessment of fluoroquinolone related QT-interval prolonging drug interactions encountered when treating uncomplicated urinary tract infections in women residing in long-term care

(252) Effect of Drug-Drug Interaction Between Tamoxifen and CYP2D6-inhibiting Antidepressants on Cancer Recurrence and Mortality of Women with Breast Cancer: a Systematic Review

(254) Opioid overdose risk after oxycodone initiation during CYP3A4-inhibiting vs non-inhibiting calcium channel blocker therapy

(255) Risk of Severe Uterine Bleeding of Oral Anticoagulants use in Postmenopausal Women Aged 55 Years or Older: An Application of the U.S. Sentinel Routine Querying Tools to the Taiwan Sentinel Data Model

(256) Lithium Toxicity Following Co-prescription of Lithium and Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin II Receptor Blockers (ARBs)

(257) The risk of fatal opioid overdose associated with the concurrent use of opioid analgesics and psychotropic medicines: a retrospective population-based cohort study

(258) The Association between Recently Elevated Anticholinergic Burden and the Risk of Delirium: a case-cross-over study